MedTrace Logo

Vitamin D and Calcium Homeostasis for Prevention of Type 2 Diabetes

NCT00436475 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 92

Last updated 2019-07-30

Study results available
· View outcomes & findings →

Summary

The purpose of the randomized trial is to quantify the effect of vitamin D and calcium supplementation on beta-cell function, insulin sensitivity, glucose tolerance and systemic inflammation and other cardiometabolic outcomes in ambulatory adults at high risk for type 2 diabetes.

Conditions

Interventions

DRUG

Vitamin D3 2,000 IU orally once daily

Vitamin D3 2,000 IU orally once daily

DRUG

Calcium Carbonate 400 mg orally twice daily

Calcium Carbonate 400 mg orally twice daily

DRUG

Vitamin D3-Placebo

Vitamin D3-Placebo

DRUG

Calcium-Placebo

Calcium-Placebo

Sponsors & Collaborators

  • National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

    collaborator NIH

  • Tufts Medical Center

    lead OTHER

Principal Investigators

  • Anastassios G Pittas, MD MS · Tufts Medical Center

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
FACTORIAL

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2007-09-30
Primary Completion
2009-11-30
Completion
2009-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00436475 on ClinicalTrials.gov